| 张 娜,贾永前,青胜兰,徐 锋,周 婕.地西他滨联合CAG方案对急性髓系白血病患者血清IFN-γ，HBDH与LDH水平的影响[J].现代生物医学进展英文版,2017,17(25):4963-4966. |
| 地西他滨联合CAG方案对急性髓系白血病患者血清IFN-γ，HBDH与LDH水平的影响 |
| Curative Efficacy of Decitabine Combine with CAG Gegimen in Treatment of Acute Myeloid Leukemia and Its Effects on IFN-γ, HBDH and LDH Levels |
| Received:February 28, 2017 Revised:March 24, 2017 |
| DOI：10.13241/j.cnki.pmb.2017.25.040 |
| 中文关键词: 地西他滨 急性髓系白血病 γ干扰素 γ-羟丁酸脱氢酶 乳酸脱氢酶 |
| 英文关键词: Decitabine Acute myeloid leukemia Interferon-γ Alpha hydroxybutyrate dehydrogenase Lactate dehy- drogenase |
| 基金项目:四川省自然科学基金项目（2011J0183） |
|
| Hits: 264 |
| Download times: 214 |
| 中文摘要: |
| 摘要 目的：研究地西他滨联合CAG方案对急性髓系白血病患者血清γ干扰素(IFN-γ)、α-羟丁酸脱氢酶(HBDH)与乳酸脱氢酶(LDH)水平的影响。方法：选取2013年2月至2016年10月我院接诊的70例急性髓系白血病患者作为本次研究对象，并按照随机数表法分为观察组(35例)和对照组(35例)。两组患者均采用常规治疗，对照组在基础治疗上，加用CAG方案，静脉注射阿克拉霉素，每次20 mg；粒细胞集落刺激因子，每次300 μg；皮下注射阿糖胞苷，每次10~15 mg/m2；观察组在对照组基础上，加用15 mg/m2地西他滨静脉滴注治疗。观察和比较两组患者的临床疗效，治疗前后血清IFN-γ、 HBDH、LDH水平的变化及不良反应的发生情况。结果：治疗后，观察组总有效率显著高于对照组[91.42%(32/35) vs. 68.57%(24/35)](P＜0.05)；血清IFN-γ、HBDH、LDH水平显著低于对照组[(3.21±1.01)pg/mL vs. (5.13±1.90)pg/mL，(103.62±26.39)U/L vs. (118.80±28.60)U/L，(101.36±27.32)U/L vs. (123.08±30.59)U/L](P＜0.05)；不良反应总发生率显著亦明显低于对照组[20.00%(7/35) vs. 42.85%(15/35)](P＜0.05)。结论：地西他滨联合CAG方案治疗急性髓系白血病患者的临床疗效优于单用CAG方案，可能与其显著降低患者血清IFN-γ、HBDH与LDH的水平有关。 |
| 英文摘要: |
| ABSTRACT Objective: To study the curative efficacy of decitabine combine with CAG regimen in the treatment of acute myeloid leukemia and its effects on the serum Interferon-γ(IFN-γ), alpha hydroxybutyrate dehydrogenase (HBDH) and lactate dehydrogenase (LDH) levels. Methods: 70 cases of patients with acute myeloid leukemia who were treated from February 2013 to October 2016 in our hospital were selected as research objects. According to the random number table, the patients were divided into the observation group (n=35) and the control group (n=35). Both groups of patients were treated conventional treatment. The control group was treated with CAG scheme, intravenous injection of aclarubicin, 20 mg each time, granulocyte colony stimulating factor, 300 μg each time, subcuta- neous intravenous cytarabine, 10~15 mg/m2 each time, while the observation group was treated with intravenous drip of decitabine on the basis of control group, 15 mg/m2 each time. Then the therapeutic effect, serum interferon-γ(IFN-γ), alpha hydroxybutyrate dehydroge- nase (HBDH), lactate dehydrogenase(LDH ) levels before and after treatment, incidence of adverse reactions were compared between two groups. Results: After treatment, the total effective of observation group was significantly higher than that of the control group[91.42%(32/35)vs68.57%(24/35)](P＜0.05); the serum IFN-γ, HBDH, LDH levels were significantly higher than those of the control group[(3.21±1.01)pg/ml vs. (5.13±1.90)pg/mL, (103.62±26.39)U/L vs. (118.80±28.60)U/L, (101.36±27.32)U/L vs. (123.08±30.59)U/L](P＜0.05); the incidence rate of adverse reactions was significantly lower than that of the control group[20.00%(7/35) vs.42.85%(15/35)(P＜0.05)]. Conclusion: Decitabine combined with CAG regimen was more effective for acute myeloid leukemia than CAG regimen alone, which might be related to reduce the serum levels of IFN-γ, HBDH and LDH. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
